Full Year Results and Business Update Presentation

• AnteoTech Ltd presents its FY2026 Full Year Results and Business Update
• The company reported a sales revenue of A$968,878 for FY2026
• AnteoTech achieved significant progress in its commercialization efforts
• The company is targeting sales growth in multiple markets including Europe, India, USA, South Korea, and Japan
• AnteoTech is focusing on converting customer evaluations into sales and expanding its product portfolio

AnteoTech Ltd (ASX: ADO) has released its Full Year Results and Business Update for FY2026. The company reported a sales revenue of A$968,878, with notable progress in commercialization efforts. AnteoTech is focusing on expanding its market presence in Europe, India, USA, South Korea, and Japan. The company is also working on converting customer evaluations into sales and expanding its product portfolio. Key highlights include a 5-year contract with Serum Institute of India, ongoing trials of new products, and the expansion of sales channels. AnteoTech's strategy is centered around leveraging its proprietary chemical platform to develop and commercialize solutions for the battery materials and life sciences markets.

AnteoTech is optimistic about converting customer evaluations into sales and expanding its product portfolio in FY2027. The company aims to progress CLIA strategic partnerships, enter the ELISA market, and convert sales of Anteo S, Anteo C, and Anteo X. Additionally, AnteoTech plans to progress Ultranode 70 commercial cell format evaluation and explore consumer battery market opportunities.